Company Profile
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Latest News
Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued
Brown-Forman Board Issues Statement
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study
You Retired With $600K in a 401(k) and No Idea What Comes Next. These 4 ETFs Are the Income Plan
Here’s Why SCHD is Beating the S&P 500 in 2026 YTD
| Sector | Healthcare |
| Industry | Medical Devices |
| Website | https://www.penumbrainc.com |
| Audit Risk | 7 |
| Board Risk | 5 |
| Overall Risk | 5 |
| Market Cap | 12.54B |
| Trailing P/E | 73.61 |
| Forward P/E | 51 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 4.33 |
| Forward EPS | 6.25 |
| Book Value | 37.48 |
| Price-to-Book | 8.5 |
| Enterprise-to-Revenue | 8.35 |
| Enterprise-to-EBITDA | 59.5 |
| Short Ratio | 5.71 |
| Earnings Date | 07/28/2026 |
| Earnings Call Date | |
| Earnings Average | 1.18 |
| Earnings Low | 1.05 |
| Earnings High | 1.27 |
| Revenue Average | 390.08M |
| Revenue Low | 384.86M |
| Revenue High | 397.00M |